Please try another search
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People’s Republic of China. The company’s pharmaceutical products include injections, capsules, tablets, and other drugs for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, parenteral nutrition, hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B and chronic hepatitis C, respiratory tract infections, urinary tract infections, genitourinary system infections, intra-abdominal infections, bone and joint infections, septicemia, catabolism, hypermetabolism, pneumonia, skin and soft tissue infections, pelvic inflammatory, diarrhea and digestive system relevant illness, biliary tract infection, and other infections. It also offers marketing and promotion services of drugs. The company was founded in 2001 and is headquartered in Hangzhou, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Qiuqin Wang | 43 | 2018 | CEO & Chairman |
Yang Liu | 40 | 2020 | Executive Chairman |
Zhihong Huo | 43 | 2018 | Executive Director |
Xueping Chu | 49 | 2021 | Executive Director |
Chi Kin Leung | 73 | 2013 | Independent Non Executive Director |
Sin Ming Li | 47 | 2017 | Independent Non-Executive Director |
Lai Yin Sy | 42 | 2018 | Independent Non-Executive Director |
Wan Zhou | 33 | 2023 | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review